Current Immunotherapeutic Approaches in Pancreatic Cancer

Table 3

DC-based vaccines.

Patients	DC-based vaccines	Response	Ref
12 pancreatic and biliary cancer patients with resected tumors	MUC1 peptide-loaded DC	4 of the 12 patients followed for over four years were alive.	[88]
10 patients with advanced breast, pancreatic, or papillary cancer	DC transfected with MUC1 cDNA	A vaccine-specific delayed-type hypersensitivity (DTH) reaction was observed in 3 out of 10 patients.	[89]
		4 patients showed a 2- to 10-fold increase in the frequency ofMUC1-specific IFN-gamma-secreting CD8+ T cells.
1 patient who could not continue chemotherapy due to sever neutropenia	DC transfected with hTERT mRNA	The patient showed no evidence of active disease based on PET/CT scans.	[93]
		The patient developed an immune response against several hTERT-derived Th and CTL epitopes.
49 patients with advanced pancreatic cancer refractory to standard chemotherapy	Peptide (WT1, MUC1, CEA, and CA125)-loaded DC	2 patients showed complete remission (CR), 5 partial remission (PR) and 10 stable disease (SD).	[94]
	Gemcitabine/S-1	Median survival time was 360 days.